BioCentury
ARTICLE | Company News

FDA rejects Noven's generic fentanyl

September 29, 2005 1:59 AM UTC

NOVN dropped $2.50 (16%) to $13.06 on Wednesday after it and partner Endo (ENDP) announced that FDA will not approve an ANDA for the partners' transdermal fentanyl patch to treat chronic pain. FDA sto...